Xiaochen (Molly) Zhao
About Xiaochen (Molly) Zhao
Xiaochen (Molly) Zhao is the Associate Director of Clinical Pharmacology & Pharmacometrics at Bristol-Myers Squibb with extensive experience in translational research, molecular biology, and drug metabolism.
Company
Xiaochen (Molly) Zhao is currently employed at Bristol-Myers Squibb, holding the position of Associate Director in Clinical Pharmacology & Pharmacometrics. Bristol-Myers Squibb is a global biopharmaceutical company primarily focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases.
Title
Xiaochen Zhao serves as the Associate Director of Clinical Pharmacology & Pharmacometrics at Bristol-Myers Squibb. In her current role, she is responsible for driving clinical pharmacology strategies to optimize drug development and ensure the safety and efficacy of new therapies.
Previous Roles at Bristol-Myers Squibb
Before her current role, Zhao advanced through multiple positions at Bristol-Myers Squibb. She worked as a Senior Research Investigator in Clinical Pharmacology & Pharmacometrics from 2017 to 2019 and as a Research Investigator in the same department from 2015 to 2017. Throughout her tenure, she has been instrumental in various pharmacometric evaluations and model-based drug development projects.
Education and Expertise
Xiaochen Zhao holds a Ph.D. in Pharmaceutical Sciences from the University at Buffalo, earned between 2010 and 2015, and a Master's Degree in Pharmacology and Pharmacokinetics from China Pharmaceutical University, obtained from 2000 to 2004. Additionally, she has expertise in Translational Research, Molecular Biology, and Drug Metabolism. Her education has set a solid foundation for her impactful work in clinical pharmacology and pharmacometrics.
Professional Background
Xiaochen Zhao began her research career as a Research Assistant at China Pharmaceutical University's National Drug Screening Center from 1998 to 2000. She then moved on to serve as a Research Assistant at the University of Toledo from 2004 to 2009. She also gained industry experience as a Clinical Pharmacology Intern at Pfizer in Groton, CT, in 2012. These roles helped hone her research skills and prepared her for advanced positions in clinical pharmacology.
Publication and Research Contributions
Zhao co-authored a publication titled 'Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types,' which appeared in the Annals of Oncology in February 2020. This work contributed significantly to understanding nivolumab's clinical applications, underscoring her role in advancing therapeutic strategies.